Search Tag: European Medicines Agency (EMA)

Executive Health Management

Emas-conclusion-on-janssen-vaccine-and-blood-clots

2021 21 Apr

The European Medicines Agency has completed its safety review for Johnson & Johnson’s COVID-19 Vaccine Janssen giving conclusions similar to those on AstraZeneca’s Vaxzevria.   You might also like: EMA announced that the single dose Covid-19 vaccine has been approved for use in individuals 18 years of age and older in the European...Read more

Executive Health Management

Perfect-storm-for-astrazeneca-covid-19-vaccine-in-eu

2021 14 Mar

AstraZeneca’s COVID-19 vaccine has been the centre of attention in Europe over the past few days. Several countries has suspended its administration after reports of a number of thromboembolic events and several deaths. This has been exacerbated by the company’s inability to meet its contractual obligations in the EU on the medicine delivery....Read more

Executive Health Management

Ema-developments-for-sputnik-v-and-janssen-covid-19-vaccines

2021 05 Mar

The European Medicines Agency (EMA) has launched a rolling review of the Russian Sputnik V vaccine and is convening to potentially finalise the COVID-19 Vaccine Janssen’s marketing authorisation.   You might also like: The European Ombudsman is investigating the European Commission’s refusal to give public access to...Read more

Executive Health Management

Fda-mhra-revoke-covid-19-authorisations-for-hydroxychloroquine

2020 16 Jun

The U.S. Food and Drug Administration has revoked its emergency use authorisation for chloroquine and hydroxychloroquine as treatments for COVID-19. The U.K. Medicines and Healthcare products Regulatory Agency has followed suit, but Brazil criticised the decision and expanded the drugs’ use.   You might also like: Warnings about Potential...Read more

Executive Health Management

Ema-fast-tracking-procedures-for-covid-19-medicines

2020 11 May

The European Medicines Agency (EMA) has published an overview of initiatives for acceleration of the regulatory procedures. This is aimed at making COVID-19-related medicines’ marketing authorisation available in the shortest possible timeframes.   You may also like: COVID-19: No Approval for Chloroquine from EMA  ...Read more